Abstract:Abstract Multi-tyrosine kinase inhibitors (TKIs) like sunitinib bind to over 50 kinases and inhibit several receptors such as VEGFR-1, VEGFR-2, and VEGFR-3 receptors, PDGFRa and PDGFRb, RET, cKIT, and FLT3. TKIs are effective drugs for the treatment of renal cell carcinoma (RCC) but intrinsic/acquired resistance remains a major hurdle. One of the proposed models for TKI resistance is drug sequestration by lysosomes. The solute transporter xCT is a cystine/glutamate antiporter that plays a role in the production of antioxidants in cancer cells. Our lab has found that SLC7A11, the gene that encodes xCT, is overexpressed in sunitinib resistant RCC cells. LAMP1 expression was also increased in sunitinib resistant RCC cells, suggesting an upregulation of lysosome biogenesis. The biochemical knock down of SLC7A11 by shRNA showed a decrease in LAMP1 expression, suggesting a decrease in lysosome biogenesis. SEC24D is a key catalytic component of COPII complex involved in formation of exosomes and secretory pathways. Our preliminary data showed that reduction in xCT expression was associated with a decrease in SEC24D protein levels which was associated with a reduction in the extracellular export and, consequently, an increase in intracytoplasmic levels of miRNA 605, a known tumor suppressor. We are currently testing the hypothesis that xCT may modulate lysosomes biogenesis and micro-RNA trafficking in several clear cell and translation renal cell carcinoma models. In summary, a better understanding of the role of xCT in the regulation of intracytoplasmic organelles may lead to the identification of a novel therapeutic strategy to overcome TKI resistance in RCC. Citation Format: Abbas Jawadwala, Christopher Rupert, Remi Adelaiye-Ogala, Roberto Pili, Sreenivasulu Chintala, Ashley Orillion, May Elbanna, Nur Damayanti, Ilaria Delle Fontane. The solute transported xCT (SLC7A11) modulates lysosome biogenesis and microRNA trafficking in drug resistant renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7584.

YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

Integrated Genomic and Proteomic Analyses Identify PYGL As a Novel Experimental Therapeutic Target for Clear Cell Renal Cell Carcinoma

YAP-Activated SATB2 is a Coactivator of NRF2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma

HDAC8 Enhances the Function of HIF-2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC

ZDHHC2-mediated AGK palmitoylation activates AKT/mTOR signaling to reduce sunitinib sensitivity in renal cell carcinoma

The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis

YY1 downregulation underlies therapeutic response to molecular targeted agents

RRM2 Regulates Sensitivity to Sunitinib and PD‐1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway

TAF1D promotes tumorigenesis and metastasis by activating PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma

EFHD1, a novel mitochondrial regulator of tumor metastasis in clear cell renal cell carcinoma

Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway

The ubiquitin ligase STUB1 suppresses tumorigenesis of renal cell carcinomas through regulating YTHDF1 stability

Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma

YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer

Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma

Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin

Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma

Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation

Abstract 7584: The solute transported xCT (SLC7A11) modulates lysosome biogenesis and microRNA trafficking in drug resistant renal cell carcinoma